ClinicalTrials.gg
CompletedNCT02612454Updated Nov 3, 2026

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

A Phase 3 interventional study of Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 84 sites in 7 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Non-randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
2nd of 50
880 · median 75
Started
2015
with 3 others
Phase 3
11 of 50
none open now
Registered
13th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2015, is one of 11 in phase 3, and was the 13th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.

The secondary objectives of the study are:

  • To assess the long-term efficacy of dupilumab in pediatric participants with AD
  • To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab

Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to \<12 years of age with AD

Co-Primary Objectives are:

  • To evaluate the pharmacokinetic (PK) of dupilumab PFPs
  • To evaluate the safety of dupilumab PFPs

Secondary Objective is:

- To evaluate the immunogenicity of dupilumab PFPs

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participated in a prior dupilumab study in pediatric participants with AD and adequately completed the visits and assessments required for both the treatment and follow-up periods, as defined in the prior study protocol
  • PFP Sub-Study Only:
  • Age ≥2 to \<12 years at time of screening
  • Body weight ≥5 kg and \<60 kg at time of screening
  • Must have received the same dupilumab dose regimen to be used in the PFP sub-study during the previous 12 weeks in the main OLE study using the prefilled syringe, as defined in the protocol

Key Exclusion Criteria:

  • Participants who, during their participation in a prior dupilumab study developed an adverse event (AE) or serious adverse event (SAE) deemed related to study drug which could indicate that continued treatment with study drug may present an unreasonable risk for the patient
  • Participants, who during the participation in a prior Dupilumab study, developed an AE that was deemed related to study drug and led to study treatment discontinuation, which in the opinion of the investigator or medical monitor could indicate that continued treatment with study drug may present an unreasonable risk for the patient
  • Treatment with an drug, other than dupilumab, within 8 weeks or within 5 half-lives (if known), whichever is longer, before the baseline visit
  • Having used /immunomodulating drugs within 4 weeks before the baseline visit
  • Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit
  • Diagnosed active endoparasitic infections or at high risk of these infections
  • Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the participant's participation in the study
  • PFP Sub-study Only:
  • Poor compliance as defined by having missed 1 or more of the planned last 3 injections in the main OLE study prior to entering the sub-study
  • Switched dupilumab doses within the past 12 weeks
  • Meet criteria for temporary/permanent discontinuation of study drug at time of screening into PFP sub-study, as defined in the protocol.

Note: Other protocol defined Inclusion / Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
880 participants (actual)

Study arms

  • Experimental
    Body weight ≥60 kg

    Administered every two weeks (Q2W)

    Drug: Dupilumab

  • Experimental
    Body weight 30 kg to <60 kg

    Administered Q2W

    Drug: Dupilumab

  • Experimental
    Body weight 15 kg to <30 kg

    Administered every 4 weeks (Q4W)

    Drug: Dupilumab

  • Experimental
    Body weight 5 kg to <15 kg

    Administered Q4W

    Drug: Dupilumab

Interventions

  • Weight-tiered dosing administered subcutaneous (SC)

    Also known as: DUPIXENT®, REGN668, SAR231893

06

What researchers measure

Primary outcomes

  1. Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit

    Time frame: Baseline up to week 272

  2. Number of participants with at least one TEAE per participant year from baseline through the last study visit

    Time frame: Baseline up to week 272

  3. OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)

    Peak serum concentration after multiple doses of dupilumab administered using the PFP (test) relative to the prefilled syringe (reference)

    Time frame: Up to week 16

  4. OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)

    Drug concentration in serum after multiple doses of dupilumab administered using the PFP (test) relative to the prefilled syringe (reference)

    Time frame: Up to week 16

  5. OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-study

    Time frame: Up to week 16

  6. OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-study

    Time frame: Up to week 16

Secondary outcomes

  1. Number of treatment-emergent serious adverse events (SAEs) from baseline through the last study visit

    Time frame: Baseline up to week 272

  2. Incidence of TEAEs of special interest from baseline through the last study visit

    Time frame: Baseline up to week 272

  3. Proportion of participants with an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  4. Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI from baseline of parent study) response at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  5. Change from baseline in EASI score at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  6. Percent change from baseline in EASI at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  7. Change from baseline in Body Surface Area (BSA) affected by AD (BSA) at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  8. Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at all in-clinic visits post-baseline

    Time frame: Baseline up to week 272

  9. Change from baseline in Children's Dermatology Life Quality Index (CDLQI) for participants ≥4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed

    Time frame: Baseline up to week 272

  10. Change from baseline in Infants' Dermatology Quality of Life Index (IDQOL) for participants <4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed

    Time frame: Baseline up to week 272

  11. Proportion of responders (defined as participants with IGA 0 or 1) who maintain IGA 0 or 1 during at least 75% of the subsequent* visits during the treatment period

    \*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.

    Time frame: Baseline to week 260

  12. For responders (defined as participants with IGA 0 or 1), median percentage of subsequent* visits during the treatment period, at which IGA 0 or 1 is maintained

    \*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.

    Time frame: Baseline to week 260

  13. Number of AD flares during the study

    AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment

    Time frame: Baseline to week 272

  14. Annualize event rate of AD flares during the study

    AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment

    Time frame: Baseline to week 272

  15. Proportion of participants with at least one flare during the study

    AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment

    Time frame: Baseline to week 272

  16. Proportion of well-controlled weeks

    Well-controlled weeks are those for which participants or parents/caregivers answer "Yes" AND during which no rescue treatments were administered

    Time frame: Baseline to week 272

  17. OPTIONAL SUB-STUDY: Incidence and titer of treatment-emergent anti-drug antibodies (ADA) (PFP Sub-Study)

    Time frame: Up to 16 weeks

07

Study locations

84 sites
  • Regeneron Investigational Site
    Birmingham, Alabama 35209, United States
  • Regeneron Investigational Site
    Gilbert, Arizona 85234, United States
  • Regeneron Investigational Site
    Bakersfield, California 93309, United States
  • Regeneron Investigational Site
    Long Beach, California 90808, United States
  • Regeneron Investigational Site
    Los Angeles, California 90027, United States
  • Regeneron Investigational site
    Mission Viejo, California 92691, United States
  • Regeneron Investigational Site
    Orange, California 92868, United States
  • Regeneron Investigational Site
    Palo Alto, California 92304, United States
  • Regeneron Investigational Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Investigational Site
    San Diego, California 92123, United States
  • Regeneron Investigational Site
    Centennial, Colorado 80112, United States
  • Regeneron Investigational Site
    Washington D.C., District of Columbia 20016, United States
  • Regeneron Investigational Site
    Coral Gables, Florida 33146, United States
  • Regeneron Investigational Site
    Tampa, Florida 33613, United States
  • Regeneron Investigational Site
    Tampa, Florida 33624, United States
  • Regeneron Investigational Site
    Columbus, Georgia 31904, United States
  • Regeneron Investigational Site
    Macon, Georgia 31217, United States
  • Regeneron Investigational Site
    Sandy Springs, Georgia 30328, United States
  • Regeneron Investigational Site
    Chicago, Illinois 60611, United States
  • Regeneron Investigational Site
    Skokie, Illinois 60077, United States
  • Regeneron Investigational site
    Plainfield, Indiana 46168, United States
  • Regeneron Investigational Site
    Rockville, Maryland 20850, United States
  • Regeneron Investigational Site
    Boston, Massachusetts 02115, United States
  • Regeneron Investigational Site
    Boston, Massachusetts 02116, United States
  • Regeneron Investigational Site
    Ypsilanti, Michigan 48197, United States
  • Regeneron Investigational Site
    Plymouth, Minnesota 55441, United States
  • Regeneron Investigational Site
    St Louis, Missouri 63104, United States
  • Regeneron Investigational Site
    Forest Hills, New York 11375, United States
  • Regeneron Investigational Site
    New York, New York 10029, United States
  • Regeneron Investigational Site
    Rochester, New York 14642, United States
  • Regeneron Investigational Site
    Gahanna, Ohio 43230, United States
  • Regeneron Investigational Site
    Portland, Oregon 97239, United States
  • Regeneron Investigational site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Investigational Site
    Charleston, South Carolina 29425, United States
  • Regeneron Investigational Site
    North Charleston, South Carolina 29420, United States
  • Regeneron Investigational Site
    Bellaire, Texas 77401-3505, United States
  • Regeneron Investigational Site
    Fort Worth, Texas 76244, United States
  • Regeneron Investigational Site
    San Antonio, Texas 78218, United States
  • Regeneron Investigational Site
    Norfolk, Virginia 23502, United States
  • Regeneron Investigational Site
    Seattle, Washington 98105, United States
  • Regeneron Investigational Site
    Calgary, Alberta T2G 1B1, Canada
  • Regeneron Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • Regeneron Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • Regeneron Investigational Site
    Markham, Ontario L3P 1X2, Canada
  • Regeneron Investigational Site
    Ottawa, Ontario K2C 2N3, Canada
  • Regeneron Investigational Site
    Peterborough, Ontario K9J 5K2, Canada
  • Regeneron Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Regeneron Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • Regeneron Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • Regeneron Investigational Site
    Kutná Hora, 28401, Czechia
  • Regeneron Investigational Site
    Prague, 10034, Czechia
  • Regeneron Investigational Site
    Ústí nad Labem, 40113, Czechia
  • Regeneron Study Site
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Regeneron Investigational Site
    Frankfurt am Main, Hesse 60590, Germany
  • Regeneron Investigational Site
    Münster, North Rhine-Westphal 48149, Germany
  • Regeneron Investigational Site
    Dresden, Saxony 01307, Germany
  • Regeneron Investigational Site
    Gera, 07548, Germany
  • Regeneron Investigational Site
    Hamburg, 22149, Germany
  • Regeneron Investigational Site
    Munich, 80337, Germany
  • Regeneron Study Site
    München, 80802, Germany
  • Regeneron Investigational Site
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Regeneron Investigational Site
    Kaposvár, 7400, Hungary
  • Regeneron Investigational Site
    Miskolc, 3526, Hungary
  • Regeneron Investigational Site
    Szeged, 6720, Hungary
  • Regeneron Investigational Site
    Ostrowiec Świętokrzyski, Kielce 27-400, Poland
  • Regeneron Investigational Site
    Wroclaw, Lower Silesian Voivodeship 50-381, Poland
  • Regeneron Investigational Site
    Wroclaw, Lower Silesian Voivodeship 50368, Poland
  • Regeneron Investigational Site
    Krakow, Malopolska 30 363, Poland
  • Regeneron Investigational Site
    Krakow, Malopolska 31-011, Poland
  • Regeneron Investigational Site
    Katowice, Silesian Voivodeship 40-648, Poland
  • Regeneron Investigational Site
    Bialystok, 15 453, Poland
  • Regeneron Investigational Site
    Bydgoszcz, 85-065, Poland
  • Regeneron Investigational Site
    Chorzów, 41-500, Poland
  • Regeneron Investigational Site
    Gdansk, 80-152, Poland
  • Regeneron Investigational Site
    Katowice, 40 611, Poland
  • Regeneron Investigational Site
    Krakow, 30 363, Poland
  • Regeneron Investigational Site
    Lodz, 90-265, Poland
  • Regeneron Investigational Site
    Warsaw, 01-142, Poland
  • Regeneron Investigational Site
    Warsaw, 01-817, Poland
  • Regeneron Investigational Site
    Warsaw, 02-758, Poland
  • Regeneron Investigational Site
    Warsaw, 91-142, Poland
  • Regeneron Investigational Site
    London, Greater London SE1 7EH, United Kingdom
  • Regeneron Investigational Site
    Manchester, Lancashire M13 9WL, United Kingdom
  • Regeneron Investigational Site
    Sheffield, South Yorkshire S10 2TH, United Kingdom
08

References and documents

Publications

  • Paller AS, Siegfried EC, Bansal A, Xiao J, Khokhar FA, Van Spall M, Liu X, Xu C, Dubost-Brama A, Kosloski MP. Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged <12 years with atopic dermatitis. Br J Clin Pharmacol. 2026 Nov 4. doi: 10.1002/bcp.70895. Online ahead of print. PubMed 42980500 ↗
  • Paller AS, Pinter A, Wine Lee L, Aschoff R, Zdybski J, Schnopp C, Khokhar FA, Praestgaard AH, Bansal A, Shumel B, Bastian M. Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis. Paediatr Drugs. 2026 May;28(3):307-320. doi: 10.1007/s40272-026-00747-4. Epub 2026 Apr 2. PubMed 41926052 ↗
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Arkwright PD, Pinter A, Deleuran M, Hong HC, Ma Y, Bansal A, Dubost-Brama A, Nguyen TV. Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis. Am J Clin Dermatol. 2026 May;27(3):611-620. doi: 10.1007/s40257-026-01018-1. Epub 2026 Mar 28. PubMed 41903092 ↗
  • Kamal MA, Kosloski MP, Lai CH, Partridge MA, Rajadhyaksha M, Kanamaluru V, Bansal A, Shabbir A, Shumel B, Ardeleanu M, Richards SM, Yan H, Xu CR, Rodriguez-Marco A, Xiao J, Khokhar FA, Gherardi G, Babilonia E, Maloney J, Mortensen E, Akinlade B, Braunstein N, Stahl N, Torri A, Davis JD, DiCioccio AT. Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis. Front Immunol. 2024 Nov 11;15:1466372. doi: 10.3389/fimmu.2024.1466372. eCollection 2024. PubMed 39588375 ↗
  • Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, Khokhar FA, Xiao J, Dubost-Brama A, Bansal A. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024 Jul;25(4):655-668. doi: 10.1007/s40257-024-00859-y. Epub 2024 May 14. PubMed 38743155 ↗
  • Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A, Levit NA. Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2023 Nov;13(11):2697-2719. doi: 10.1007/s13555-023-01016-9. Epub 2023 Sep 26. PubMed 37750994 ↗
  • Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. PubMed 35567671 ↗
  • Paller AS, Tan JKL, Bagel J, Rossi AB, Shumel B, Zhang H, Abramova A. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. Br J Dermatol. 2022 Mar;186(3):496-507. doi: 10.1111/bjd.20872. Epub 2022 Feb 25. PubMed 34726270 ↗
  • Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1. PubMed 33481203 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Oct 2026, 131 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 131 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2015
First posted
Nov 23, 2015
StartActual
Oct 15, 2015
Primary completionActual
Oct 9, 2026
CompletionActual
Oct 9, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 3, 2026
Primary completion
Oct 7, 2026→Oct 9, 2026 (actual)
Nov 3, 2026
Study completion
Oct 7, 2026→Oct 9, 2026 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Primary completion Oct 7, 2026→Oct 9, 2026 (now actual)
    Study completion Oct 7, 2026→Oct 9, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02612454
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Oct 15, 2015
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Nov 3, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion